The Latest Cardiac and Vascular News
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) — World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy’s Board of Directors. Dr. Henry is the Lindner Family Distinguished Chair in Clinical Research and Medical Director of The Carl and Edyth Lindner Center for Research at The Christ Hospital […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the appointment of Dr. Russell Greig, as independent Chairman of its Board of Directors. Dr. Greig brings more than 35 years of experience in the pharmaceutical industry from GlaxoSmithKline, with […]
In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported outcomes Tyvaso DPI safety confirmed through 51 weeks of optional extension phase data with no study drug-related serious adverse events FDA action on […]
Former GE Healthcare Chief Digital Officer joins group of new leaders spearheading RapidAI’s product innovation; advancing patient care for Pulmonary Embolism, Aneurysm and Stroke globally SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in neurovascular and vascular imaging driving the next evolution of clinical decision making and patient workflow, today announced […]
WASHINGTON, April 4, 2022 /PRNewswire/ — Edward T. A. Fry, MD, FACC, today begins his one-year term as president of the American College of Cardiology, a nonprofit cardiovascular medical society representing over 54,000 cardiologist and cardiovascular care team members around the world. “I am looking forward to learning from and working with ACC’s […]
MENLO PARK, Calif., April 5, 2022 /PRNewswire/ — Endovascular Engineering (“E2”), a privately-held developer of next-generation thrombectomy devices to treat patients with Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), today announced the closing of a $15 million Series A1 financing. The financing was co-led by Santé Ventures and Cordis, who were joined by […]
Combined Company to Spearhead Transformation of Cardiovascular Disease Drug Discovery and Development BOSTON, April 5, 2022 /PRNewswire/ — Valo Health, LLC (“Valo”), announced today the acquisition of TARA Biosystems, Inc. (“TARA”), a New York City-based cardiovascular disease biotechnology company, creating the first of its kind vertically integrated cardiovascular drug discovery and development platform. The combination of TARA’s proprietary […]
MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms. Jiny Kim, MBA to CytoSorbents’ Board of Directors as a new independent director, effective immediately, for a term expiring at […]
First clinical trial to evaluate the safety & efficacy of RT234 on exercise parameters assessed by Cardiopulmonary Exercise Testing (CPET) PALO ALTO, Calif., April 5, 2022 /PRNewswire/ — Respira Therapeutics, Inc. a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of […]
–Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle– –Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications– DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company […]
